MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

NCT02955368 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-06-05

No results posted yet for this study

Summary

The purpose of this study is to determine superiority of DP-R212 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Conditions

Interventions

DRUG

DP-R212

DP-R212 + C1-R212 placebo + C2-R212 placebo

DRUG

C1-R212

DP-R212 placebo + C1-R212 + C2-R212 placebo

DRUG

C2-R212

DP-R212 placebo + C1-R212 placebo + C2-R212

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2017-07-31
Completion
2017-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02955368 on ClinicalTrials.gov